Esperion Therapeutics | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
AbbVie USD 10.71B 458M 2024-12
Alnylam Pharmaceuticals USD 523.15M 32.8M 2025-03
Amarin USD 25.13M 1.78M 2025-03
Amgen USD 5.54B 430M 2025-03
Biogen USD 1.87B 44.1M 2024-12
BioMarin Pharmaceutical USD 593.59M 17.59M 2025-03
Cipla INR 45.41B 4.9B 2025-03
CSL USD 4.28B 939M 2024-12
Cytokinetics -160545000 81.19M 2024-09
Daiichi Sankyo JPY 424.35B 67.89B 2025-03
Eli Lilly USD 10.5B 624.7M 2025-03
Geron 38.4M 8.36M 2025-03
Grifols EUR 766.49M 39.74M 2024-12
Halozyme Therapeutics USD 216.46M 39.49M 2025-03
Ionis Pharmaceuticals USD 130.15M 92.6M 2025-03
Merck USD 12.77B 849M 2025-03
Moderna USD 17M 403M 2025-03
Pfizer USD 11.12B 987M 2025-03
PTC Therapeutics USD 196.89M 10.95M 2024-12
Regeneron Pharmaceuticals USD 2.56B 659.4M 2025-03
Sanofi EUR 7.72B 2.36B 2025-03
Sarepta Therapeutics USD 607.29M 81.18M 2025-03
United Therapeutics USD 701.9M 41.9M 2025-03



Esperion Therapeutics Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Jul 2025.